Lupin Gets USFDA Approval for Lenalidomide Capsules

Lupin Limited announced on September 17, 2025, that it has received approval from the United States Food and Drug Administration (USFDA) for its Lenalidomide capsules, the generic equivalent of Revlimid manufactured by Bristol-Myers Squibb Company. The drug is a widely used therapy for multiple myeloma and related conditions, representing a major growth opportunity for the Mumbai-based pharmaceutical company.

Details of the Approval

The approval covers Lenalidomide capsules in strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg. According to the company’s exchange filing, the product will be manufactured at Lupin’s Pithampur facility in India.

Lenalidomide is prescribed for patients with multiple myeloma, both in combination with dexamethasone and as maintenance therapy following autologous hematopoietic stem cell transplantation (auto-HSCT).

Therapeutic Applications

Beyond multiple myeloma, the drug is also approved for the treatment of transfusion-dependent anaemia caused by myelodysplastic syndromes (MDS). Specifically, it is indicated for patients with low- or intermediate-1-risk MDS associated with a deletion 5q abnormality, with or without additional cytogenetic abnormalities.

With estimated annual sales of $7.5 billion in the US market, Lupin’s entry into this space represents a significant opportunity to expand its oncology portfolio.

Manufacturing and Market Significance

The approval enables Lupin to manufacture the capsules at its Pithampur facility, strengthening its presence in the high-value oncology generics segment. The move aligns with the company’s strategy of building capabilities in complex generics and specialty therapies, particularly in regulated markets like the US.

The availability of a bioequivalent version of Revlimid is expected to improve patient access by lowering treatment costs.

USFDA Observations at Nagpur Facility

Earlier in the day, Lupin was also in the spotlight after the USFDA issued six observations for its Nagpur injectable facility. The company confirmed that it would address the concerns within the stipulated timeframe.

“We will address the observations and respond to the USFDA within the stipulated timeframe. We are committed to be compliant with current good manufacturing practices (CGMP) quality standards across all our facilities,” Lupin told CNBC TV18.

Following the update, Lupin shares traded in the red despite the positive regulatory approval.

Read More: Welcure Drugs Share Price Hits Upper Circuit

Conclusion

The USFDA approval for Lenalidomide capsules marks a milestone for Lupin, giving it access to a multi-billion-dollar opportunity in the US oncology market. While the observations at its Nagpur plant present near-term challenges, the company’s commitment to regulatory compliance positions it to strengthen its long-term growth trajectory in critical therapies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.